NEW YORK (GenomeWeb) – A University of California, San Francisco-led research team found that Agendia's MammaPrint 70-gene panel can identify breast cancer patients with ultralow-risk of late recurrence, or patients who might benefit from less endocrine-based treatment than is currently recommended by the breast cancer oncology community.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.